Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
$0.40
-0.2%
$0.43
$0.19
$1.27
$1.93M0.84727,259 shs68,057 shs
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
$1.81
-0.3%
$1.52
$1.15
$23.80
$2.98M0.61.33 million shs110,435 shs
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$3.26
0.0%
$3.66
$2.85
$29.44
$5.35M0.0388,525 shs4,783 shs
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
$0.02
+1.3%
$0.02
$0.01
$0.58
$644K1.061.08 million shs31,733 shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
0.00%+6.60%-22.31%-17.55%-62.24%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
0.00%-0.28%+19.54%+45.56%-51.54%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00%-8.69%-13.09%+3.79%-76.72%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
0.00%-8.99%-4.71%-28.63%-96.55%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
2.1113 of 5 stars
3.25.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
0.00
N/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
2.00
HoldN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
0.00
N/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
2.33
Hold$1.7510,702.47% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
N/AN/AN/AN/A($0.82) per shareN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/A$9.87 per shareN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
$4.98M1.07N/AN/A($4.12) per share-0.79
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/AN/AN/AN/A$0.33 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
-$18.06MN/A0.00N/AN/A-1,063.82%-26.06%N/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
-$7.52M-$16.66N/AN/AN/A-32.21%-28.59%8/26/2025 (Estimated)
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
-$6.26MN/A0.00N/AN/AN/AN/A8/13/2025 (Estimated)
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
-$51.06M-$1.10N/AN/AN/A-1,899.61%-114.21%8/12/2025 (Estimated)

Latest VIRX, QLGN, GLMD, and ENTO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/22/2025Q1 2025
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A-$0.62N/A-$0.62N/AN/A
5/15/2025Q1 2025
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
N/A-$0.21N/A-$0.28N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
N/AN/AN/AN/AN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/AN/AN/AN/AN/A
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
N/A
2.90
2.90
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
N/A
9.02
9.02
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
N/A
2.33
2.33
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
N/A
0.76
0.76

Institutional Ownership

CompanyInstitutional Ownership
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
12.30%
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
76.14%
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
3.18%
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
31.37%
CompanyEmployeesShares OutstandingFree FloatOptionable
Entero Therapeutics, Inc. stock logo
ENTO
Entero Therapeutics
94.77 million4.73 millionN/A
Galmed Pharmaceuticals Ltd. stock logo
GLMD
Galmed Pharmaceuticals
201.65 million1.33 millionNot Optionable
Qualigen Therapeutics, Inc. stock logo
QLGN
Qualigen Therapeutics
501.64 million1.61 millionNot Optionable
Viracta Therapeutics, Inc. stock logo
VIRX
Viracta Therapeutics
2039.74 million35.50 millionOptionable

Recent News About These Companies

Viracta Therapeutics Shuts Down Operations, Lays Off All Staff
Viracta Therapeutics terminates employees, to wind down operations
Viracta Therapeutics Announces Wind Down of Operations
Viracta Therapeutics Inc (VIRX) Stock Trading Recap
VIRX’s Unexpected Surge: What’s Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Entero Therapeutics stock logo

Entero Therapeutics NASDAQ:ENTO

$0.40 0.00 (-0.25%)
Closing price 07/3/2025 02:33 PM Eastern
Extended Trading
$0.40 0.00 (0.00%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:GLMD

$1.80 -0.01 (-0.28%)
Closing price 07/3/2025 03:40 PM Eastern
Extended Trading
$1.84 +0.03 (+1.66%)
As of 04:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Qualigen Therapeutics stock logo

Qualigen Therapeutics NASDAQ:QLGN

$3.26 0.00 (-0.03%)
Closing price 07/3/2025 03:10 PM Eastern
Extended Trading
$3.26 0.00 (-0.09%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Viracta Therapeutics stock logo

Viracta Therapeutics NASDAQ:VIRX

$0.02 +0.00 (+1.25%)
As of 07/3/2025 12:58 PM Eastern

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.